• M Schley, S Topfner, K Wiech, H E Schaller, C J Konrad, M Schmelz, and N Birbaumer.
• Department of Anaesthesiology and Intensive Care Medicine, Experimental Pain Research/Pain Centre, University of Heidelberg, Faculty of Clinical Medicine, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. marcus.schley@anaes.ma.uni-heidelberg.de
• Eur J Pain. 2007 Apr 1;11(3):299-308.

BackgroundHyperexcitability of N-methyl-d-aspartate acid (NMDA) receptors may play an important role in the development of phantom limb pain (PLP).Aim Of The StudyTo investigate whether early treatment with the NMDA antagonist memantine attenuates phantom pain memory formation in traumatic amputees.MethodsIn a randomized, double-blind, controlled trial 19 patients with acute traumatic amputation of the upper extremity were investigated. All patients received postoperative analgesia by continuous brachial plexus anesthesia (ropivacaine 0.375% 5 ml/h) for at least 7 days. In addition, the patients received either memantine (20-30 mg daily, n=10) or placebo (n=9) for 4 weeks.ResultsMemantine treatment reduced the number of requested ropivacacine bolus injections during the first week and resulted in a significant decrease of PLP prevalence and intensity at 4 weeks and 6 months follow up, but not at 12 months follow up.ConclusionsWe conclude that memantine can reduce intensity of phantom limb pain and might also prevent the development of PLP. However, despite the very early begin of treatment; no long-term effect on established PLP was evident.

48 keywords...

hide…